Location History:
- University City, MO (US) (1993)
- St. Louis, MO (US) (1992 - 2010)
Company Filing History:
6 out of 1,586 
1 out of 245 
6 out of 832,843 Years Active: 1992-2010
Title: The Innovations of Sondra Schlesinger: Pioneering Recombinant Alphavirus Research
Introduction
Sondra Schlesinger, an accomplished inventor based in St. Louis, MO, has made significant contributions to the field of virology through her innovative research and numerous patents. With a remarkable portfolio of 13 patents, she continues to advance the understanding and application of recombinant alphavirus-based vectors.
Latest Patents
One of Schlesinger's latest patents focuses on recombinant alphavirus-based vectors that exhibit reduced inhibition of cellular macromolecular synthesis. This patent discloses isolated nucleic acid molecules comprising an alphavirus nonstructural protein gene. When incorporated into a recombinant alphavirus particle or RNA vector replicon, these molecules result in a reduced level of vector-specific RNA synthesis compared to wild-type. Importantly, they maintain the same or greater level of proteins encoded by RNA transcribed from the viral junction region promoter when compared to a wild-type recombinant alphavirus particle. Furthermore, this patent encompasses RNA vector replicons, alphavirus vector constructs, and eukaryotic layered vector initiation systems containing these nucleic acid molecules.
Career Highlights
Sondra Schlesinger has held positions at prestigious institutions, including Washington University. Her work in this esteemed environment has enabled her to push the boundaries of research and enhance the efficacy of vectors used in various applications, such as gene therapy and vaccine development.
Collaborations
During her career, Schlesinger has collaborated with esteemed colleagues, including Thomas W. Dubensky, Jr. and John M. Polo. Their combined expertise has undoubtedly fostered innovative approaches and breakthroughs in the field of virology.
Conclusion
Sondra Schlesinger stands as a prominent figure in the realm of recombinant virology, with her inventive work shaping the future of therapeutic and research applications. Her dedication to innovation and collaboration continues to inspire the scientific community and advance our understanding of viral mechanisms.